IRA side ef­fect: Phar­ma com­pa­nies will in­creas­ing­ly skip Medicare al­to­geth­er, Lil­ly CEO says

As the Cen­ters for Medicare and Med­ic­aid Ser­vices races to fi­nal­ize guid­ance on how it will ne­go­ti­ate — or dic­tate, de­pend­ing on if you ask a phar­ma ex­ec — the prices of the costli­est med­i­cines in the US, phar­ma ex­ecs are warn­ing of un­want­ed reper­cus­sions.

Eli Lil­ly CEO David Ricks told JP Mor­gan an­a­lysts on Wednes­day that for some new drugs, com­pa­nies might just skip out on seek­ing en­try in­to the Medicare pro­gram al­to­geth­er.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER